Recent Advances in Metal Radionuclides
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Inorganic Chemistry".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 1973
Special Issue Editors
Interests: radiopharmaceutical; nuclear mdicine; molecular Imaging; inorganic chemistry; coordination chemistry
Special Issue Information
Dear Colleagues,
Radiopharmaceuticals embodying metal radionuclides nowadays represent both a solid reality for clinical application and one of the most important fields of research in different disciplines ranging from chemistry, material science, physics, and nuclear medicine.
The large variety of radiometals already available along with the extensive group of those that are potentially producible offer a vast array of emissions and decay modes, guaranteeing the so-called “theragnostic approach” in the detection and treatment of oncological diseases. A peculiar feature of metal-containing radiotracers is the presence of tailored chelator moieties in the chemical structure of the biological vector. While the chelators firmly bind the radionuclide, avoiding unsought widespread radioactivity in no-target organs, the targeting vectors selectively direct the emitted radiation to the cancer sites. Examples of tumour-targeting probes include a large number of small molecules, peptides, and antibody derivatives embracing several biological processes and pathways.
You are cordially invited to contribute to this Special Issue, “Recent Advances in Metal Radionuclides”, with original articles as well as reviews and short communications. Areas of interest include, but are not limited to, the following:
- Production and separation of innovative radiometals;
- New chelators moiety for radiometals: synthesis and performances;
- Innovative labelling methods: processes and technologies;
- Radiometals containing radiopharmaceuticals: synthesis and preclinical studies;
- Theragnostic radiopharmaceuticals;
- Innovative metal labelled targeting vector for nuclear imaging or therapy.
Dr. Mattia Asti
Dr. Marianna Tosato
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- radiometals
- theragnostic
- chelators
- radiotracers
- nuclear medicine
